Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Public Storage (PSA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Public Storage — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while Public Storage trades at $324.41 (market cap $60.82B). The key difference: Public Storage is far larger — about 12× ACADIA Pharmaceuticals Inc.'s market cap, and Public Storage pays a 3.68% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | PSA | |
|---|---|---|
Market Cap | $5.06B | $60.82B |
Sector | Health | Real Estate |
52-Week High | $29.41 | $330.47 |
52-Week Low | $20.06 | $258.44 |
Enterprise Value | $4.18B | $75.10B |
Dividend Yield | — | 3.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.21, up 2.67% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.18 versus $0.07 expected, driven by robust Daybue and Nuplazid sales, leading to a raised 2026 revenue outlook. The stock shows high profitability with a net margin of 33.42% and ROE of 35.74%, though valuation metrics like EV/EBITDA of 42.2 indicate premium pricing.
The outlook is positive with 70% analyst buy ratings and a $33 consensus target, but risks include reliance on key drugs and Phase 2 trial results for remlifanserin due by October 2026. Cash flow volatility from heavy investing outlays in 2025 warrants monitoring, but operational strength supports growth potential.
Public Storage (PSA) trades at $328.40, up 0.43% on the day, with a bullish technical signal from moving averages and a consensus price target of $333.88. The company reported Q2 2026 EPS of $2.55, beating estimates, and raised full-year guidance following the acquisition of National Storage Affiliates. Strong profitability is evident with a net income margin of 41.8% and ROE of 37.42%, though valuation multiples like P/E of 31.34 suggest a premium.
Outlook remains positive due to accretive acquisitions and dividend stability, with a $3.00 quarterly dividend declared. Risks include high valuation, interest rate sensitivity, and integration challenges from recent deals. Analyst sentiment is mixed with 28.6% buy ratings, but institutional activity shows both position increases and cuts, indicating cautious optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →
